https://orcid.org/0000-0001-5951-0900
References
- Monahan C , McCoy L , Powell J , et al. Olanzapine/samidorphan: new drug approved for treating bipolar I disorder and schizophrenia. Ann Pharmacother. 2022:106002802110703.
- Bidlack JM , Knapp BI , Deaver DR , et al. In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder. J Pharmacol Exp Ther. 2018;367(2):267–281.
- Shram MJ , Silverman B , Ehrich E , et al. Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent μ-Receptor Antagonist. J Clin Psychopharmacol. 2015;35(3):242–249.
- Wesson DR , Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003; 35(2):253–259.
- Berlin D , Farmer BM , Rao RB , et al. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification – New York City, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(38):777–780.
- Naranjo CA , Busto U , Sellers EM , et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
- Kunzler NM , Wightman RS , Nelson LS. Opioid withdrawal precipitated by long-acting antagonists. J Emerg Med. 2020;58(2):245–253.